Medical Board


Meet Our Medical Advisors

Meet the amazing men and women who help babies affected by Congenital Diaphragmatic Hernia not only in the Operating Room, Intensive Care Unit and the Laboratory but they help families by volunteers for our charity as well.

Our Medical Advisory Board participates in our CDH Conferences, proofs our materials and research projects, participates in other events such as the International Day of Congenital Diaphragmatic Hernia Awareness, lobbies with us for more research funding and works with our charity and other members of ACDHO to better the CDH Community

 

N. Scott Adzick, MD, MMM, FACS, FAAP – Children’s Hospital of Philadelphia

N Scott Adzick, MD Dr. Adzick is the C. Everett Koop Professor of Pediatric Surgery at CHOP and the founder and director of the Hospital’s Center for Fetal Diagnosis and Treatment. He also serves as CHOP’s Surgeon-in-Chief, Director of the Division of Pediatric General, Thoracic and Fetal Surgery, and Professor of Pediatrics, Obstetrics and Gynecology at the University of Pennsylvania School of Medicine.

A true innovator in the field of fetal medicine since its inception, Dr. Adzick has dedicated his career to the pursuit of groundbreaking prenatal treatment for debilitating birth defects. He has made pioneering contributions to the practice of fetal surgery, and today continues to explore cutting edge surgical treatment options for life-threatening fetal anatomic malformations such as urethral obstruction, congenital diaphragmatic hernia, congenital cystic adenomatoid malformation of the lung, and sacrococcygeal teratoma.

Dr. Adzick was the principal investigator for the National Institutes of Health (NIH) “Management of Myelomeningocele Study” (MOMS) at CHOP. This breakthrough study demonstrated that performing fetal surgery for spina bifida results in significantly improved outcomes versus conventional postnatal repair. The study represents the fruition of decades of research, much of it led by Dr. Adzick and his team, and is an example of how a once-radical idea can, though meticulous investigation, be transformed into a viable treatment for patients. Dr. Adzick is lead author of the study results, published in the New England Journal of Medicine.

“For the first time in the history of mankind, we have a new way to offer hope to families who have a diagnosis of spina bifida,” says Dr. Adzick. “It’s very gratifying to take an idea we had 20 years ago, test it thoroughly, apply it cautiously in the clinical setting and, eventually, have the ability to offer a new therapy that can completely change the life of a child.”

Dr. Adzick earned his bachelor’s degree from Harvard College, his medical degree from Harvard Medical School, completed his surgical residency at Massachusetts General Hospital in Boston and his pediatric surgery fellowship at Boston Children’s Hospital. He holds a Masters of Medical Management degree from Carnegie Mellon University.

Dr. Adzick was a postdoctoral scholar at the University of California San Francisco, where he was an attending surgeon from 1988 until 1995, when he was recruited to The Children’s Hospital of Philadelphia as Surgeon-in-Chief.

Dr. Adzick has had NIH grant support for more than 20 years and has authored more than 500 peer-reviewed publications. He is recognized worldwide for his contributions to the field of pediatric surgery, and for his creative leadership at CHOP to enhance the surgical care of children.

(biography credit to CHOP)

Patricia Donahoe, MD – Massachusetts General Hospital

Patricia Donahoe, MDPatricia K. Donahoe is Director of Pediatric Surgical Research Laboratories and Chief Emerita of Pediatric Surgical Services at Massachusetts General Hospital where she has worked virtually her entire career, and the Marshall K. Bartlett Professor of Surgery (Tenured) at Harvard Medical School. She received her MD from Columbia University in New York City, New York, and BS from Boston University in Boston, Massachusetts where she currently serves on the Board of Trustees. She is a member and past Chair of the Scientific Advisory Board at St. Judes Medical Center and has been a member of the Scientific Advisory Board at Memorial Sloan-Kettering Cancer Center and of the NICHD National Advisory Council. She has published over 230 peer-reviewed publications in developmental biology concentrating on Mullerian Inhibiting Substance as a potential anticancer agent against human ovarian carcinomas, as well as the genetics of sex differentiation and a number of other congenital anomalies for which she has been steadily funded by the NIH. Dr. Donahoe and her colleagues, particularly David MacLaughlin, hold a number of patents on MIS. They purified the human MIS, cloned the MIS gene and that of its receptors, studied their regulation and their roles in the growth, diagnosis, and treatment of ovarian and other reproductive tumors, and used MIS as a marker in the diagnosis of human tumors in human intersex disorders.

She is a member of the National Academy of Sciences, Institute of Medicine of the National Academy of Sciences, and American Academy of Arts and Sciences. Dr. Donahoe served as President of the Boston Surgical Society and is President-elect of the American Pediatric Surgical Association. She has received many research prizes and honorary degrees for her work on MIS, but her fondest dream is to see it developed as a therapeutic for ovarian and other reproductive cancers.

(biography credit to Harvard University)

Wendy Chung, MD, PhD - Columbia Presbyterian / DHREAMS

Wendy Chung, MDWendy Chung, MD, PhD, is a clinical and molecular geneticist who directs the clinical genetics program at Columbia University and currently has a grant from the Children's Cardiomyopathy Foundation to identify new genes for infantile cardiomyopathy. The goal of her research is to identify new genes for susceptibility to cardiac disease and to develop individualized risk assessment, prevention, and therapeutic interventions for HCM. Clinically, she directs programs in risk assessment for cardiomyopathy and arrhythmias and develops novel molecular diagnostic methods to improve genetic testing including pre-implantation genetic diagnosis for family planning.

She lectures and writes on the legal and social issues raised by genetic testing in asymptomatic individuals, disparities is access to genetic care, confidentiality and privacy of genetic information, and defining conditions for which prenatal genetic testing is or is not appropriate. A recipient of the American Academy of Pediatrics Young Investigator Award and the Herbert Irving assistant professor of pediatrics and medicine, Dr. Chung received her B.A. in biochemistry and economics from Cornell University, her M.D. from Cornell University Medical College, and her Ph.D. from The Rockefeller University in genetics.

(biography credit to Columbia Presbyterian)

Jan Deprest, MD, PhD - University Hospital Gasthuisberg, Leuven, Belgium


Jan Deprest, MDQualifications: 1985 MD (KU Leuven), 1991 Specialist (Ob/Gyn), 1995 PhD (KU Leuven), FRCOG (2012)


Present position:

Professor of Obstetrics and Gynaecology, Faculty of Medicine (KU Leuven)

Academic Chair Woman and Child (till 2011); Academic Chair Department of Development and Regeneration (2012-2017) at the Faculty of Medicine.

Director Inter-departmental Centre for Surgical Technologies, Faculty of Medicine, KU Leuven

Consultant in Obstetrics and Gynaecology (University Hospitals Leuven)
“Zorgprogramma” (Programme) Fetal Medicine, Director Fetal Therapy
“Zorgprogramma” (Programme) Urogynaecology, co director with Dirk De Ridder

Scientific Activities:

  • Published 340 peer-reviewed papers in scientific journals
  • Over 80 book chapters
  • Supervised/supervises over 23 doctoral students in research in fetal medicine or pelvic floor medicine
  • Developed instruments and operations in the field of fetal therapy, applied research in biomechanics for pelvic floor medicine.

(biography credit to the World Congress of Pediatric Surgery)

David Kays, MD – Shands for Kids / University of Florida at Gainesville

David Kays, MDDr. Kays has led an effort to improve outcome from congenital diaphragmatic hernia (CDH) that has made UF Health Shands Children’s Hospital one of the recognized world leaders in the clinical care of this condition. Utilizing a protocol focused on strict protection of the infant’s lungs, survival in newborns with CDH delivered at UF Health is now close to 90 percent.

Dr. Kays has carefully documented and analyzed this experience and is actively investigating new methods to further improve outcomes. He directs the Shand’s ECMO program and holds leadership positions in the Extracorporeal Life Support Organization. He is currently involved in a collaboration with the hopes of improving brain protection in children with CDH and those on ECMO. Dr. Kays’ main research interests include Congenital Diaphragmatic Hernias, Neonatal Ventilation, Congenital Anomalies, Pectus Carinatum and Pectus Excavatum.

(biography credit to the University of Florida)

Kevin Lally, MD, MS, FACS - University of Texas Medical School at Houston

Kevin Lally, MD, MS, FACS

Dr. Lally is the A.G. McNeese Chair in Pediatric Surgery, Richard Andrassy Distinguished Professor and Chairman of the Department of Pediatric Surgery. He is Surgeon-in-Chief of the Children's Memorial Hermann Hospital and Director of the ECMO Program. Dr. Lally completed his Pediatric Surgery Training at the Children's Hospital of Los Angeles and is board certified in Surgery, Critical Care and Pediatric Surgery. Dr. Lally is one of the world’s leading experts in Congenital Diaphragmatic Hernias (CDH). He developed and runs the CDH Registry, which in an international consortium that has prospectively collected data on over 6,000 infants with this rare anomaly. He is actively involved in student and resident education and the Center for Clinical Trials and Evidence Based Surgery. Dr. Lally has been principal investigator or co-investigator on several clinical trials.

(biography credit to the University of Texas)

Paul Losty, MD FRCSI FRCS(Eng) FRCS(Ed) FRCS(Paed) – Liverpool University, UK

Paul LostyExternal Collaborations • Action Medical Research, Horsham, West Sussex, Action Medical Research • Oxford Radcliffe Hospitals NHS Trust, National Perinatal Epidemiology Unit Oxford University , Dr Marian Knight and Dr Jenny Kurinczuk

Internal Collaborations • University of Liverpool, Human Anatomy and Cell Biology, Dr D Moss • University of Liverpool, Child Health, Mr EC Jesudason
• University of Liverpool, Biological Sciences, School of, Prof MR White and Dr D Spillar
• University of Liverpool, Biological Sciences, School of, Prof DG Fernig and Prof J Turnbull

Research Awards: Principal Investigator • Cellular Models for Studying Lung Abnormalities in Congenital Diaphragmatic Hernia. • Exploiting mechanical stimuli to increase prenatal growth of the hypoplastic lung.
• Physiology of the pulmonary pacemaker: a new regulator of prenatal lung growth.
• Exploiting mechanical stimuli to increase prenatal growth of the hypoplastic lung.
• Sonographic measurement of peristalsis in normal human fetal airway.
• Endothelial-vascular smooth muscle interactions in the hypertensive hypoplastic perinatal lung.

(biography credit to the Liverpool Cancer Center)

Steadman McPeters, CPNP – Huntsville Alabama, Pediatric Surgery Nurse Clinician


Steadman McPetersAlso a CDH Survivor.

Bio coming soon.

Doug Miniati, MD – University of California, San Francisco

Neonates with congenital diaphragmatic hernia (CDH) represent a fascinating challenge to those who are involved in their care. Great strides have been made to improve our perinatal and perioperative care for these patients, leading to increased survival. However, a wide spectrum of disease severity exists, from the few, who are cured with a single procedure, to the majority, who suffer long-term sequelae related pulmonary insufficiency and gastrointestinal dysfunction. Much remains to be understood regarding both normal and abnormal lung development and response to various stimuli, and more importantly, regarding the advancement of new and effective therapeutic strategies for patients with CDH.

The Miniati lab focuses on 1) furthering our understanding of the mechanisms of CDH-associated lung hypoplasia in both teratogenic and genetic mouse models, and 2) developing prenatal pharmacologic treatments and in utero mechanical means to promote optimal lung function in the ovine CDH model. Other developing areas of interest include the human genetics of CDH and continued long-term outcomes analyses of children in our multidisciplinary CDH clinic. Through collaborations with colleagues in the Lung Biology Center, the UC Berkeley/UCSF Bioengineering Program, and the divisions of neonatology and pediatric intensive care, we are gaining more insight into how this disease occurs and how to treat it, ultimately leading to improved quality of life for both patients and their families.

(biography credit to UCSF)


Henry Rice, MD – Duke University Medical Center

Henry Rice, MD Division Chief, Pediatric General Surgery

Departments / Divisions
Surgery / Pediatric General Surgery
Pediatrics / Pediatrics-Chairman Office

Training
        • MD, Yale University School of Medicine (Connecticut), 1988
Residency
  • General Surgery, University of Washington Medical Center, 1996
Fellowship
  • Pediatric Surgery, Children's Hospital of Buffalo (New York), 1998

Clinical Interests
Neonatal surgery, prenatal counseling, general pediatric thoracic and abdominal surgery

(biography credit to Duke University)

Edmund Yang, MD – OSF / Univeristy of Illinois

Title(s): Clinical Associate Professor of Surgery - University of Illinois College of Medicine at Peoria

Medical Education: Vanderbilt University (Nashville, TN)

Internship(s): General Surgery - University of California at San Francisco (San Francisco, CA; 1993-1994)

Residency: General Surgery - University of California at San Francisco (San Francisco, CA; 1994-2001)

Fellowship(s): Pediatric Surgery - Boston Children's Hospital (Boston, MA; 2001-2003)

Board Certification(s): Pediatric Surgery - American Board of Surgery

Professional Certification(s): Advanced Trauma Life Support (ATLS)

Clinical Interests: Fetal Intervention, Neonatal Surgery, Minimally Invasive Surgery

Professional Memberships: American Academy of Pediatrics, National Board of Medical Examiners, American Board of Surgery, American Pediatric Surgical Association, International Pediatric Endosurgery Group, International Fetal Medicine & Surgery Society

Awards & Recognition: Farley Fellowship - Boston Children's Hospital (2002), Chief Resident - University of California at San Francisco General Surgery Department (2000-2001), Von L. Meyer Fellowship Fund - Boston Children's Hospital (2001), British Association of Pediatric Surgeons Award (1998), Medical Scientist Training Program Award - National Institute of General Medicine (1987-1993), Guest Research Award - National Heart, Lung, & Blood Institute (1986-1987), Cystic Fibrosis Foundation Award (1996-1998), Former Principal Investigator - Management of Myelomeningocele Study

(bio credit to OSF)



Past Medical Advisors for CHERUBS have included:

  • Jay M. Wilson, MD
  • Michael R. Harrison, MD
  • Beth Zimmerman, RN
  • Prem Puri, MD
  • Jacob Langer, MD
  • Vincent Adolph, MD
  • Aviva Katz, MD
  • Lesli Taylor, MD

 

 
Join the Angel Club and make a monthly or annual donation in honor or in memory of your cherub.

Donation Amount Options
In honor or memory of who?